Aleksander G. Rumyantsev

Aleksander G. Rumyantsev

Auto-generated profile, based on publicly available information

Aleksander G. Rumyantsev

National Scientific and Practical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2024 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
SVS.V. Voronin
S.V. Voronin
EZEKATERINA ZAKHAROVA
EKATERINA ZAKHAROVA
GBG.V. Baydakova
G.V. Baydakova
AMAndrey Marakhonov
Andrey Marakhonov
Olga ShchaginaOlga Shchagina
Olga Shchagina
SKSergei I. Kutsev
Sergei I. Kutsev
Under the implementation of the “Advanced neonatal screening” Federal Program and the Ministry of Healthcare of Russia Order No. 274n “On approval of the Procedure for providing medical care to patients with congenital and/or hereditary diseases” that started jointly on Jan. 01, 2023 overall Russia, the examination of all newborns for the 29 nosologies of exchange disorders by tandem mass spectrometry as well as spinal muscular atrophy and primary immunodeficiencies by polymerase chain reaction had begun. Circa 1 million and 230 thousand newborns were examined in 85 Russia regions during 2023 with the level of births coverage exceeding 98%. As a result, a risk group that amounted to 1.86% of all examined was formed with confirming diagnostics performed for 8712 neonatal patients at risk, of which 676 have had their deceases confirmed including 379 hereditary metabolic diseases, 117 spinal muscular atrophies and 180 primary immunodeficiencies. Effective treatment and dispensary follow-up methods have been developed so far for all the screened nosologies. Thus, the introduction of the neonatal screening made it possible to initiate therapy for most of the identified patients at preclinical stages reducing the overall infant mortality and improving the quality of life for such patients and their caretakers.

26 June 2024 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
ENE. L. Nasonov
E. L. Nasonov
ARA. G. Rumyantsev
A. G. Rumyantsev
MSMikhail Samsonov
Mikhail Samsonov
Autoimmunity is a pathological process associated with a violation of immunological tolerance to normal structural components of the body (autoantigens), associated with the predominance of active (adaptive) immunity and manifested by hyperproduction of autoantibodies. Systemic autoimmune rheumatic diseases (SARDs) are among the most common and severe nosological forms of this pathology associated with autoimmunity. Problems of pharmacotherapy of SARDs are the subject of intensive research. At the beginning of the 21st century, more than 20 biologic agents were developed for the treatment of rheumatoid arthritis – monoclonal antibodies (mAbs) and recombinant proteins that control inflammation associated with the overproduction of “pro-inflammatory” cytokines, the use of which has dramatically improved the results of pharmacotherapy. However, much less research has been devoted to studying the possibilities of pharmacotherapy aimed at selective suppression of the “autoimmune” component of the pathogenesis of SADRs associated with uncontrolled activation of B cells and restoration of immunological tolerance to autoantigens. In the spectrum of drugs whose mechanism of action is associated with the suppression of pathological activation of B cells, the leading place is occupied by rituximab (RTM). It is noteworthy that 20 years ago (2004), a group of researchers led by prof. J.C. Edwards first demonstrated the effectiveness of RTM in patients with RA, which was soon successfully repositioned to treat a wide range of SARDs. A major achievement in the pharmacotherapy of SARDs is associated with the use of CAR (сhimeric antigen receptor) T cell therapy, developed for the treatment of refractory hematological tumors. The main component of CART-cells is a genetically engineered T-cell receptor that recognizes the target antigen without the participation of the major histocompatibility complex. Although limited, extremely impressive data regarding high remission rates have been obtained by adapting CD19 CART-cell therapy to treat patients with severe systemic lupus erythematosus (SLE) and other SARDs refractory to standard immunosuppressive medications. The article discusses the results of the use of CART-cell therapy in SLE and other SARDs and prospects for further research.

14 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SSSoslan Shakhidzhanov
Soslan Shakhidzhanov
AFAnna Filippova
Anna Filippova
EBElizaveta A. Bovt
Elizaveta A. Bovt
AGAndrew Gubkin
Andrew Gubkin
GSGennady T. Sukhikh
Gennady T. Sukhikh
FAFazoil Ataullakhanov
Fazoil Ataullakhanov
Introduction: Severely ill COVID-19 patients receiving prophylactic-dose anticoagulation exhibit high rates of thrombosis and mortality. The escalation of anticoagulation also does not reduce mortality and has an uncertain impact on thrombosis rates. The reasons why escalated doses fail to outperform prophylactic doses in reducing risks of thrombosis and death in severely ill COVID-19 patients remain unclear. We hypothesized that escalated anticoagulation would not effectively prevent hypercoagulability and, consequently, would not reduce the risk of thrombosis and death in some severely ill patients. Methods: We conducted a prospective multicenter study that enrolled 3860 COVID-19 patients, including 1654 severely ill. They received different doses of low-molecular-weight or unfractionated heparin, and their blood coagulation was monitored with activated partial thromboplastin time, D-dimer, and Thrombodynamics. A primary outcome was hypercoagulability detected by Thrombodynamics. Blood samples were collected at the trough level of anticoagulation. Results: We found that escalated anticoagulation did not prevent hypercoagulability in 28.3% of severely ill patients at the trough level of the pharmacological activity. Severely ill patients with such hypercoagulability had higher levels of inflammation markers and better creatinine clearance compared to severely ill patients without it. Hypercoagulability detected by Thrombodynamics was associated with a 1.68-fold higher hazard rate for death and a 3.19-fold higher hazard rate for thrombosis. Elevated D-dimer levels were also associated with higher hazard rates for thrombosis and death, while shortened APTTs were not. The simultaneous use of Thrombodynamics and D-dimer data enhanced the accuracy for predicting thrombotic events and fatal outcomes in severely ill patients. Conclusions: Thrombodynamics reliably detects hypercoagulability in COVID-19 patients and can be used in conjunction with D-dimer to assess the risk of thrombosis and death in severely ill patients. The pharmacological effect of LMWH at the trough level might be too low to prevent thrombosis in some severely ill patients with severe inflammation and better creatinine clearance, even if escalated doses are used.

13 April 2020 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
NKN.B. Kuzmenko
N.B. Kuzmenko
YRYulia Rodina
Yulia Rodina
AKA.L. Khoreva
A.L. Khoreva
AMA.A. Moiseeva
A.A. Moiseeva
ARA.G. Rumyantsev
A.G. Rumyantsev
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.

13 April 2020 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
M9Moscow G.N. Speransky City Children’s Hospital No. 9
Moscow G.N. Speransky City Children’s Hospital No. 9
IKI.A. Korsunsky
I.A. Korsunsky
DKDmitry Kudlay
Dmitry Kudlay
APA.P. Prodeus
A.P. Prodeus
ASA.YU. Shcherbina
A.YU. Shcherbina
ARA.G. Rumyantsev
A.G. Rumyantsev
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.

10 June 2019 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
NKN.B. Kuzmenko
N.B. Kuzmenko
YRYulia Rodina
Yulia Rodina
IKI.V. Kondratenko
I.V. Kondratenko
АBА.а. Bologov
А.а. Bologov
IEIrkutsk Irkutsk State Medical Academy Of Postgraduate Education - Subsidiary Of The Russian Medical Academy For Continuous Professional Education
Irkutsk Irkutsk State Medical Academy Of Postgraduate Education - Subsidiary Of The Russian Medical Academy For Continuous Professional Education
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.